AAAAAA
Results:
1-8
|
Results: 8
Authors:
Riley, RJ
Parker, AJ
Trigg, S
Manners, CN
Citation: Rj. Riley et al., Development of a generalized, quantitative physicochemical model of CYP3A4inhibition for use in early drug discovery, PHARM RES, 18(5), 2001, pp. 652-655
Authors:
McGinnity, DF
Riley, RJ
Citation: Df. Mcginnity et Rj. Riley, Predicting drug pharmacokinetics in humans from in vitro metabolism studies, BIOCH SOC T, 29, 2001, pp. 135-139
Authors:
Soars, MG
Riley, RJ
Findlay, KAB
Coffey, MJ
Burchell, B
Citation: Mg. Soars et al., Evidence for significant differences in microsomal drug glucuronidation bycanine and human liver and kidney, DRUG META D, 29(2), 2001, pp. 121-126
Authors:
Soars, MG
Smith, DJ
Riley, RJ
Burchell, B
Citation: Mg. Soars et al., Cloning and characterization of a canine UDP-glucuronosyltransferase, ARCH BIOCH, 391(2), 2001, pp. 218-224
Authors:
McGinnity, DF
Parker, AJ
Soars, M
Riley, RJ
Citation: Df. Mcginnity et al., Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s, DRUG META D, 28(11), 2000, pp. 1327-1334
Authors:
Fowler, SM
Riley, RJ
Pritchard, MP
Sutcliffe, MJ
Friedberg, T
Wolf, CR
Citation: Sm. Fowler et al., Amino acid 305 determines catalytic center accessibility in CYP3A4, BIOCHEM, 39(15), 2000, pp. 4406-4414
Authors:
McGinnity, DF
Griffin, SJ
Moody, GC
Voice, M
Hanlon, S
Friedberg, T
Riley, RJ
Citation: Df. Mcginnity et al., Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli, DRUG META D, 27(9), 1999, pp. 1017-1023
Authors:
Moody, GC
Griffin, SJ
Mather, AN
McGinnity, DF
Riley, RJ
Citation: Gc. Moody et al., Fully automated analysis of activities catalysed by the major human liver cytochrome P450(CYP) enzymes: assessment of human CYP inhibition potential, XENOBIOTICA, 29(1), 1999, pp. 53-75
Risultati:
1-8
|